We generated a RUNX2-yellow fluorescent protein (YFP) reporter system to study osteogenic development from human embryonic stem cells (hESCs). Our studies demonstrate the fidelity of YFP expression with expression of RUNX2 and other osteogenic genes in hESCderived osteoprogenitor cells, as well as the osteogenic specificity of YFP signal. In vitro studies confirm that the hESC-derived YFP + cells have similar osteogenic phenotypes to osteoprogenitor cells generated from bone-marrow mesenchymal stem cells. In vivo studies demonstrate the hESC-derived YFP + cells can repair a calvarial defect in immunodeficient mice. Using the engineered hESCs, we monitored the osteogenic development and explored the roles of osteogenic supplements BMP2 and FGF9 in osteogenic differentiation of these hESCs in vitro. Taken together, this reporter system provides a novel system to monitor the osteogenic differentiation of hESCs and becomes useful to identify soluble agents and cell signaling pathways that mediate early stages of human bone development.
INTRODUCTION
Human embryonic stem cells (hESCs) provide an attractive alternative cell source for bone regeneration. Although recent reports demonstrated methods to generate osteogenic cells from hESCs (Arpornmaeklong et al., 2010 (Arpornmaeklong et al., , 2011 Mateizel et al., 2008) , it is difficult to evaluate the osteogenic development of hESCs and to identify specific cell populations based on surface antigen phenotypes, especially when surface antigens are not cell lineage specific. Also, assessing the homogeneity of cells during differentiation can be challenging. Therefore, a more efficient monitoring system is desirable to evaluate the osteogenic development of hESCs.
RUNX2 is known as a critical regulator (Komori, 2010; Maruyama et al., 2007; Sudhakar et al., 2001 ) during osteogenic development. RUNX2 plays an essential role upstream of osteoblastic differentiation in osteogenic specification (Hill et al., 2005) , and it induces the expression of osteogenic extracellular matrix genes during osteoblast maturation, such as collagen-Ia, alkaline phosphatase (ALP), and osteocalcin (BGLAP) (Cohen, 2009; Dalle Carbonare et al., 2012; Lian et al., 2006) . Therefore, RUNX2 initiates osteogenesis in a manner that is precisely controlled temporally and spatially, and loss of RUNX2 expression at this early stage impairs osteogenic differentiation in bone development (Otto et al., 1997; Cohen, 2013) .
To better define the kinetics of osteogenic development from hESCs and to more efficiently identify osteoprogenitor cells for clinical applications, we have generated a novel reporter system for RUNX2 expression by utilizing the RUNX2 P1 promoter driven expression of YFP. The P1 promoter directs expression of the longest RUNX2 isoform and is activated by developmental signaling pathways in mesenchymal progenitor cells (Zhang et al., 2009 ). We then stably introduced this RUNX2 P1 promoter-YFP cassette with a constitutively active luciferase (luc) gene for in vivo imaging into hESCs (H9 cell line). After verifying the reliability of this reporter system, we tracked the osteogenic differentiation using this RUNX2-YFP-integrated H9 hESCs, evaluated the efficiency of such osteogenic differentiation of hESCs, and tested the osteogenic phenotypes of these differentiated cells in vivo.
RESULTS
Integration of the Reporter System Does Not Alter the Differentiation Pattern of hESCs The RUNX2-YFP reporter was introduced to H9 hESCs using the Sleeping Beauty transposon system as previously described (Wilber et al., 2007) (Figures S1A and S1B ). Because the engineered hESCs express luciferase (luc) from a constitutive EF1a promoter, a highly enriched population of cells expressing the RUNX2-YFP construct was achieved (more than 99% luc + cells) by bioluminescent imaging and repeated selection of luc + cells ( Figure S1C ).
To test whether such genetic manipulation altered their differentiation capability, unmodified H9 hESCs and engineered RUNX2-YFP-H9 hESCs were seeded on gelatin pre-coated culture dishes and cultured in the osteogenic differentiation medium (MSC medium, including 10% characterized FBS, 1% P/S, 1% MEM-NEAA, 2 mM L-glutamine in a-MEM, and osteogenic supplements [OSs] consisting of ascorbic acid, dexamethasone, and b-glycerophosphate, termed MSC+OS medium) followed by serial passaging. Analysis of typical MSC surface antigens and YFP expression in the differentiated hESCs at passage 0, 1, and 2 demonstrated increasing CD73 + and CD105 + cells over time, with comparable cell populations between RUNX2-YFP hESCs and unmodified hESCs. YFP expression was detected only in the engineered cells ( Figures 1A  and 1B ). To verify that this differentiation was generalizable for several clonal populations of the RUNX2-YFPexpressing hESCs, the osteogenic differentiation of four additional RUNX2-YFP-H9 hESC clones have been assessed, all of which demonstrated similar differentiation patterns ( Figure S2A ). Quantitative RT-PCR (qRT-PCR) analysis of RUNX2 gene expression in the osteogenic differentiated cells derived from the RUNX2-YFP hESCs and unmodified hESCs showed comparable increase (Figure 1C) . Morphologically, both hESC lines did not show any obvious differences, with luciferase positive in the engineered hESCs and YFP fluorescence observed only in the differentiated RUNX2-YFP hESCs ( Figures 1D and S1D) . Therefore, the similar differentiation capability of both hESC lines allowed for the RUNX2-YFP-expressing hESCs Representative data from three independent experiments. (C) qRT-PCR results of RUNX2 in undifferentiated hESCs (group 1), osteogenic differentiated hESCs at p5 (group 2), undifferentiated RUNX2-YFP hESCs (group 3), and osteogenic differentiated RUNX2-YFP hESCs at p5 (group 4). GAPDH gene was used as internal control, and the Ct value was normalized to group 1. Data presented as mean ± SEM, n = 3, *p < 0.05. (D) Bright-field and fluorescent images of the unmodified and engineered H9 hESCs, in undifferentiated or differentiated conditions (scale bar, 200 mm).
to be used in the following studies evaluating their osteogenic differentiation. Figure 2C ). These results demonstrated the fidelity of the YFP reporter to monitor RUNX2 gene expression in the osteogenic differentiated hESCs. We also evaluated Collagen-Ia and SPARC genes in the sorted cell populations, which showed similar expression patterns with the highest levels in YFP + cell population ( Figure 2D ). To test the osteogenic specificity, we further evaluated YFP expression in these hESCs cultured in hematopoietic differentiation condition described in our previous study (Tian and Kaufman, 2008) . Flow cytometric analysis consistently showed that the hematopoietic differentiated CD34 + hESCs are YFP À ( Figure 2E ). Taken together, these assessments demonstrated the reliability of YFP expression to monitor RUNX2 gene activation in the osteogenic differentiated hESCs. Figure 3B , qRT-PCR analysis demonstrated that the expression levels of osteogenic genes significantly increased in the cells cultured in MSC+OS medium compared to cells cultured in MSC medium alone. The increased levels of Coll-Ia and BGLAP genes were significantly higher in BM-MSC-derived osteoprogenitor cells than in the hESC-derived cells cultured in MSC+OS medium, whereas a comparable increase of RUNX2 and SPARC genes was found. These qRT-PCR results, which demonstrate elevated osteogenic gene expression in the differentiated hESC cultured in MSC medium, are consistent with other studies (Arpornmaeklong et al., 2010 (Arpornmaeklong et al., , 2011 Karp et al., 2006) . As expected, the pluripotency gene OCT4 was reduced in both osteogenic-differentiated cell populations ( Figure S3B S3D ).
YFP
To better define the kinetics of osteogenic development in this system and to better define the developmental stages of these differentiated cells, qRT-PCR analysis of several early lineage-specific genes, BRACHYURY (T gene), HAND2, FOXC1, and PAX3, in the osteogenic differentiated hESCs was performed. These studies demonstrated that BRACHYURY(T) gene expression level only transiently increased, consistent with development of early mesoderm (Ojala et al., 2012; Ramos-Mejia et al., 2010) , followed by differentiation of this population. In contrast, expression of FOXC1 and PAX3 genes increased over time, suggesting that the early mesodermal differentiation is followed by subsequent differentiation favoring development of paraxial mesoderm (indicated by FOXC1) and neural crest (indicated by PAX3), with little differentiation into lateral plate mesoderm (as minimal expression of HAND2 was seen). These cells subsequently form mature osteoblasts after serial passaging, indicated by increased osteocalcin expression (BGLAP), in this defined osteogenic culture condition ( Figure S2B ).
To Figure 3E ), which implies intramembraneous bone formation in the calvarial defect area. Morphologically the newly formed bone tissue is different from the adjacent calvarium, which is composed of cancellous bone between cortical bones ( Figure 3E ). To identify the origin of new bone, we used an osteocalcin (OC) antibody, which recognizes either human or mouse OC in osteoblasts or deposited in the bone matrix as demonstrated in previous studies (Bielby et al., 2004; Hattori et al., 2006; Sackstein et al., 2008) . The immunostaining results confirmed the species specificity of the anti-human OC antibody ( Figure S4A ). The new bone tissue clearly stains positive for human OC ( Figure 3F ), with an area that stains for both human and mouse OC at the junction between new bone tissues where presumably active osteoblasts from both mouse and human are concentrated ( Figures  3F and S4B ). This OC distribution pattern is consistent with the histological finding that osteoblasts that produce OC are located in areas of new bone development, whereas osteocytes that produce little OC reside in area of more mature bone. Additional anti-human MHC-I staining also demonstrated similar distribution of human cells in the area of new bone formation ( Figure S4C ). These results confirm osteogenic potential of these implanted hESCderived YFP + osteoprogenitor cells. In addition to engraftment and development of human osteoblasts/osteocytes, it is also likely that the implanted human cells induced proliferation of mouse osteoblasts that contributed to the repair, as seen in similar models (Kuhn et al., 2014) . hESC-derived MSCs are known to produce cytokines and growth factors that might induce endogenous bone repair (Kopher et al., 2010; Kimbrel et al., 2014) , though specific agents that are active in this model need further elucidation in future studies. Figure 3E ) (scale bar, 38 mm). See also Figure S4 . Figure 4A ), suggesting that OS in serum-containing medium can significantly boost osteogenic differentiation of hESCs ( Figure 4A ). These results, combined with the qRT-PCR data ( Figure 3B ), suggest the superior osteogenic capability may quantitatively and qualitatively contribute to better in vivo bone formation of the cells in the MSC+OS group ( Figure 3D ). (C and D) Evaluation of cell differentiation in serum-free condition with or without OS, in the presence or absence of BMP2 or FGF9, at day 10. KOSR, 5% KOSR in place of 10% FBS in MSC media; BMP2, 50 ng/ml; FGF9, 10 ng/ml. Data are presented as mean ± SEM, n = 3, *p < 0.05. 
DISCUSSION
hESCs demonstrate the potential to serve as a starting cell population for bone regeneration, and previous studies report effective differentiation of hESCs to osteogenic lineage (Arpornmaeklong et al., 2010; Kärner et al., 2009 ). However, it remains important to better define how to obtain homogeneous osteogenic progenitor cells from hESCs. Our studies utilize a novel RUNX2 (P1)-YFP reporter system to monitor osteogenic differentiation of hESCs. Combined in vitro and in vivo studies validate the fidelity of this system to monitor the osteogenic differentiation and identify the osteogenic cell population derived from hESCs. Direct differentiation of hESCs has been reported to generate osteogenic cells with comparable osteogenic activity as the cells derived from hBM-MSC or from hESCderived MSCs (Arpornmaeklong et al., 2011) . Here, we simultaneously evaluated expression of RUNX2 and MSC surface markers to monitor the osteogenic development of hESCs in vitro. The flow cytometry data, gene expression results and in vivo study consistently demonstrated the osteogenic activity in a fraction of hESC-derived cells cultured in serum with no OS. These results are in agreement with previous studies (Arpornmaeklong et al., 2011; Harkness et al., 2011; Kuhn et al., 2014) . While addition of OS to serum enhances osteogenic differentiation of hESCs to produce a homogenous osteoprogenitor population, OS itself cannot induce such differentiation prior to development of CD73 + cells from hESCs allowed to differentiate with either serum or BMP2 in vitro. These results suggest that CD73 + cells in the differentiated hESCs might serve as an intermediary cell population to generate osteoprogenitor cells, which provides a plausible mechanism as to why addition of OS at day 14 may dramatically increase bone nodule formation by ESCs in vitro (Bielby et al., 2004; Buttery et al., 2001) . Therefore, the term ''direct osteogenic differentiation'' needs to be cautiously used when hESCs are directly exposed to osteogenic differentiation condition. The in vitro study of BMP2 provides additional insight and further demonstrates the utility of this RUNX2-YFP reporter system. Similar to a short-term study on the effect of BMP2 in human MSCs (Osyczka et al., 2004) , we also found that BMP2 does not activate RUNX2, indicated by no YFP expression. However, BMP2 does increase CD73 + cell population in hESCs cultured in serum-free conditions. These data suggest BMP2 alone does not induce osteogenic differentiation but may promote the generation of CD73 + cells first and then synergistically facilitates osteogenic differentiation when combined with OS in serum-free condition. Of course, additional detailed long-term studies will be useful to further define the osteogenic factors that mediate osteogenic development.
In conclusion, this RUNX2-YFP reporter system is a reliable tool to monitor the osteogenic differentiation of hESCs. It provides a new method to understand the differentiation stages during bone development in a human system. Likewise, this system is useful to isolate early human osteogeneic cells and to further optimize differentiation protocols to better define osteogenic development factors for both hESCs and induced pluripotent stem cells (iPSCs).
EXPERIMENTAL PROCEDURES
Creation of Vector and the Stable Cell Line and Induction of Osteogenic Differentiation of hESCs hESCs were cultured and induced osteogenic differentiation according to the protocol in Dr. Krebsbach lab (Arpornmaeklong et al., 2011) . See Supplemental Experimental Procedures for additional details.
Flow Cytometric Analysis and Fluorescent Imaging
Single-cell suspension of differentiated cells was prepared as previously described (Kopher et al., 2010) . See Supplemental Experimental Procedures for additional details.
Real-Time RT-PCR Analysis
Total RNA was abstracted and reverse transcribed into cDNA. Quantitative real-time RT-PCRs were performed. See Supplemental Experimental Procedures for additional details.
Implants Preparation and Surgical Procedure
The differentiated H9-RUNX2-YFP cells at p5$6 were used for in vivo study. See Supplemental Experimental Procedures for additional details.
Bioluminescent Imaging and microCT Measurement of Defect Repair In Vivo
The bioluminescence images of the implanted cells were visualized, and the bone formation of calvarial defect was assessed using microtomography. See Supplemental Experimental Procedures for additional details.
Histological and Immunohistochemical Study
Histological evaluation of the healing tissue in mouse calvarial defect area was performed according to our previously reported protocol (Kopher et al., 2010) . See Supplemental Experimental Procedures for additional details.
Statistical Analysis
Each experiment was repeated biologically three times independently, if not stated otherwise. As noted in the figure legends, ''n'' stands for the number of biologically independent experiments. Results were presented as mean ± SEM. Statistic analysis was performed using Microsoft Excel and Prism. One-way or two-way ANOVA was used for multiple comparisons. p values was calculated by two-tailed Student's t test, and the significant difference was defined by p < 0.05, as indicated by asterisk. 
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